Boehringer Ingelheim International Gmbh

Dr. Karl Thomae Gmbh

Boehringer Ingelheim Pharma Kg

Karl Thomae Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Kg

Orexo Ab

Boehringer Ingelheim Gmbh

Celamerck Gmbh & Co. Kg

Dr. Karl Thomae Gesellschaft MIT Beschrankter Haftung

Dr. Karl Tomae Gmbh

Boehringer Ingelehim Pharma Kg

Norbert Hauel

Wolfgang Wienen

Uwe Joerg Ries

Henning Priepke

Joachim Heider

Manfred Reiffen

Volkhard Austel

Willi Diederen

Michael Entzeroth

Iris Kauffmann-Hefner

Berthold Narr

Henri Doods

Jacques Van Meel

Annette Schuler-Metz

Jean Marie Stassen

Walter Kobinger

Herbert Nar

Christian Lillie

Angelo Ceci

Klaus Reinhold Noll

Andreas Bomhard

Jacobus C Van Meel

Roland Pfau

Frank Himmelsbach

Matthias Eckhardt

Elke Langkopf

Ingo Konetzki

Mohammad Tadayyon

Rainer Walter

Raimund Kuelzer

Manfred Psiorz

Leo Thomas

Georg Dahmann

Kai Gerlach

Kirsten Arndt

Andreas Schnapp

Sandra Handschuh

Gerhard Mihm

Klaus Klinder

Juergen Mack

Berthold Narr, Deceased

Klaus Damm

Sanjaya Singh

Michael Mark

Keith Allen Canada

Rainer Zimmermann

Alisa K Waterman

Tobias Litzenburger

Klaus Binder

Joanne Van Ryn

Dirk Stenkamp

Rudolf Hauptmann

Heiner Ebel

John Edward Park

Peter Swetly

Adolf Himmler

Rolf Dach

Gunther R Adolf

Oliver Meyer

Florian Colbatzky

Jurgen Dammgen

Helmut Heitger

Ulrich Busch

Ulrich Kunz

Jacobus C Antonius Van Meel

Walter Haarman

Iris Kaufmann-Hefner

Birgit Jung

Armin Heckel

Wolfgang Eberlein

Stefan Peters

Helmut Pieper

Peter Sieger

Roland Maier

Josef Nickl

Dieter Wiedenmayer

Wolfgang Grell

Enzo Cereda

Christopher Ronald Sarko

Johannes Keck

Gerd Kruger

Jean-Marie Stassen

Robert Copenhaver

Annerose Mauz

Rainer Zimmerman

Ulrich Brauns

Iris Kauffmann

Wolfgang Weinen

Andres Bomhard

Annette Maria Schuler-Metz

Sandra Ruth Handschuh

There are provided compounds of formula (I), wherein R, R, R, Q, Q, Q, Q, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer. 

1H-benzimidazole-5-carboxamides as anti-inflammatory agents

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds

A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1'-methylbenzimidazol-2&#x2032;-yl)benzimidazole with a compound of formula (IV) wherein Z is a leaving group, to obtain the compound 2-cyano-4&#x2032;-[2&#x2033;-n-propyl-4&#x2033;-methyl-6&#x2033;-(1&#x2032;&#x2033;-methylbenzimidazol-2&#x2032;&#x2033;-yl)benzimidazol-1&#x2033;-ylmethyl]biphenyl, and subsequently hydrolyzing the nitrile function to obtain the acid function.

Process for manufacture of telmisartan

Disubstituted tetrahydrofuranyl compounds of general formula I of which the following are exemplary: 

Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists

1H-benz imidazole-5-carboxamides as anti-inflammatory agents

The present invention relates to compounds of general formula I wherein n, R, R, R, R, R, R, Rand Rare defined as stated hereinafter, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

Bradykinin B1-antagonists

The present invention relates to the compounds of general formula I wherein Rand Rare defined as described hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the medicaments containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

Pyridazin derivatives as antagonists of the bradykinin B1 receptor

Disclosed are compounds of the formula I wherein A, Y, R, R, R, Rand Rare defined, suitable for treating diseases and symptoms of diseases caused at least to some extent by stimulation of bradykinin-B1 receptors, the preparation thereof and the use thereof.

B1-antagonists

Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof

The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and Rto Rare defined as in claim, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

Carboxylic acid amides, the preparation thereof and their use as medicaments

3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents

3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents

Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds

Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumor pain and headache diseases. The following is exemplary: 

Bradykinin B1-receptor antagonists

Growing community of inventors

Schemmerhofen, Germany

Norbert Hauel